Kato Yutaro, Tsuyuki Akira, Kikuchi Kiyoshi, Fujishiro Yasuo, Tanabe Minoru, Watanabe Masahiko, Ozawa Soji, Kitajima Masaki
Department of Surgery, Tokyo Denryoku Hospital, Tokyo, Japan.
J Gastroenterol Hepatol. 2008 Apr;23(4):673-7. doi: 10.1111/j.1440-1746.2006.03258.x.
Multiple primary cancers including small intestinal tumors are rare. We describe the first curative resection case of metachronous triple early cancers involving the jejunum as well as the stomach and esophagus. The patient had undergone total gastrectomy for a gastric adenocarcinoma and subsequent esophagectomy for an esophageal squamous cell carcinoma. A jejunal adenocarcinoma, the third primary, occurred at the blind stump of the jejunal limb of a Roux-en-Y esophagojejunostomy reconstructed previously. This tumor was removed by partial resection of the limb with the preservation of the esophagojejunostomy. The patient died from complications of acute pancreatitis 3 years after the last operation, without overt clinical signs of cancer recurrence. Immunohistochemistry of the specimen showed the increased expression of p53 and cyclin D1 proteins in all three cancers, suggesting their involvement in metachronous carcinogenesis in this case. Early diagnosis of each cancer was made possible by regular endoscopic follow-up and favorable anatomical location of each tumor, which were considered to allow less invasive surgery as well as to contribute to the favorable outcome. This case suggests the importance of regular surveillance for metachronous carcinogenesis, especially when the preceding cancers carry genetic abnormalities that may potentially increase the risk for subsequent carcinogenesis.
包括小肠肿瘤在内的多发性原发性癌症很罕见。我们描述了首例涉及空肠以及胃和食管的异时性三原发早期癌症的根治性切除病例。该患者曾因胃腺癌接受全胃切除术,随后又因食管鳞状细胞癌接受食管切除术。第三原发性空肠腺癌发生在先前重建的Roux-en-Y食管空肠吻合术空肠袢的盲端。通过保留食管空肠吻合术对该肠袢进行部分切除,切除了肿瘤。患者在最后一次手术后3年死于急性胰腺炎并发症,无明显癌症复发临床迹象。标本的免疫组织化学显示,三种癌症中p53和细胞周期蛋白D1蛋白的表达均增加,提示它们参与了该病例的异时性致癌过程。通过定期内镜随访以及每个肿瘤良好的解剖位置,实现了对每种癌症的早期诊断,这被认为既能进行侵入性较小的手术,又有助于取得良好的治疗效果。该病例表明了对异时性致癌进行定期监测的重要性,尤其是当前期癌症存在可能增加后续致癌风险的基因异常时。